This $1 Stock is a ‘Strong Buy’ with 213% Upside Potential

We recently started a series called “Penny Stock of the Day”. These ideas are geared towards traders with an extremely high risk appetite.

Our Penny Stock of the Day is chosen by screening for stocks under $5 and then applying technical analysis on the shortlisted set of penny stocks showing unusual volume. When making these trades, please make sure to pay vigilant attention to pricing moves and have a strict stop loss in place to avoid significant losses.

Penny Stock of the Day: Tenaya Therapeutics, Inc. (NASDAQ: TNYA)

Today’s penny stock pick is the clinical-stage biotechnology company, Tenaya Therapeutics, Inc. (NASDAQ: TNYA).

Tenaya Therapeutics, Inc. discovers, develops, and delivers therapies for heart disease in the United States. The company’s lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.

It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. The company has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. for discovering novel human genetic targets for the potential development of disease-modifying treatments for cardiovascular diseases.

Website:  https://www.tenayatherapeutics.com/

Latest 10-K report:  https://investors.tenayatherapeutics.com/static-files/b73ecfcf-6b4e-4041-80a1-885981a68e7f

Analyst Consensus: As per TipRanks Analytics, based on 6 Wall Street analysts offering 12-month price targets for TNYA in the last 3 months, the stock has an average price target of $3.00, which is nearly 214% upside from current levels.

Analysts | Source: TipRanks.com

Potential Catalysts / Reasons for the Hype:

• The company recently announced a research collaboration with Alnylam Pharmaceuticals (ALNY) to validate up to 15 cardiovascular gene targets. Tenaya gets an immediate $10 million upfront payment, research funding, and up to $1.13 billion in future milestones.
• Hedge Funds Increased Holdings by 178.8K Shares Last Quarter.
  

  Hedge Funds | Source: TipRanks.com

• The FDA lifted the clinical hold on the company’s MyPEAK-1 trial for TN-201 (targeting hypertrophic cardiomyopathy) late last year. Interim data showed the therapy was well-tolerated, and crucially, all patients successfully tapered off immunosuppressive medicines without adverse effects.
• Tenaya presented preclinical data for TN-301 (an HDAC6 inhibitor) targeting Duchenne muscular dystrophy (DMD). The data showed that TN-301 actually outperformed givinostat (an already FDA-approved DMD drug) in improving muscle function in models. Tenaya is now fast-tracking this into Phase 2 clinical development. There are rumors that TN-301 might actually be the hidden gem of the company’s portfolio, opening them up to the lucrative DMD and heart failure markets.

On analyzing the company’s stock charts, there seem to be multiple bullish indications…

Bullish Indications

#1 Falling Wedge Pattern Breakout: The daily chart shows that the stock has been forming a falling wedge pattern for the past several months. These are marked as purple lines. It has typically taken support at the bottom of the wedge before bouncing back. The stock has currently broken out from the falling wedge pattern and is moving higher. This is a possible bullish sign.

TNYA – Daily Chart

#2 Bullish ADX and DI: The ADX indicator shows bullishness as the +DI line is above the -DI line, and the ADX line is currently moving higher from below the +DI and -DI lines.

#3 Price above MA: The stock is currently above its 50-day SMA, indicating that the bulls have currently gained control.

#4 MACD above Signal Line: In the daily chart, the MACD (light blue color) is currently above the MACD signal line (orange color). This indicates a possible bullish setup.

#5 Above Support Area: The weekly chart shows that the stock is currently trading above a support area, which is marked as a pink dotted line. This looks like a good area for the stock to move higher. The stock is also trading above its 50-week SMA, indicating that the bulls are gaining control.

TNYA – Weekly Chart

#6 Bullish Stoch: The %K line is above the %D line of the stochastic in the weekly chart as well, indicating possible bullishness.

Recommended Trade (based on the charts)

Buy Levels: If you want to get in on this trade, the ideal buy level for TNYA is above the price of $1.00.

Target Prices: Our first target is $2.00. If it closes above that level, the second target price is $3.00.

Stop Loss: To limit risk, place a stop loss at $0.40. Note that the stop loss is on a closing basis.

Our target potential upside is 100% to 200%.

For a risk of $0.60, our first target reward is $1.00, and the second target reward is $2.00. This is a nearly 1:2 and 1:3 risk-reward trade.

In other words, this trade offers 2x to 3x more potential upside than downside.

Potential Risks / Red Flags:

1. The company has a history of net losses. As of December 31, 2024, TNYA had an accumulated deficit of $514.4 million.
   

   TNYA – Consolidated Statements of Operations

2. The reason the stock is trading under $1.00 is largely due to its financing history. In December 2025, TNYA executed a highly dilutive public offering of 50 million units at $1.20.
3. Corporate Insiders placed Informative Sells of Shares Worth $5.9M in the Last 3 Months.
   

   Insiders | Source: TipRanks.com

4. Gene therapy clinical trials are incredibly expensive. TNYA remains a pre-revenue company that is expected to continue to burn cash. Any delays in clinical trials may significantly impact the company. Gene therapies also require highly specialized, expensive manufacturing. As the company scale toward pivotal Phase 3 trials, manufacturing bottlenecks are a persistent background risk.
5. The company had received Nasdaq deficiency notice (Jan 2026) for listing compliance.
6. Despite being a loss-making company, the executives are being paid significant compensation.
   

   TNYA – Executive Compensation

As you can see, today’s featured penny stock offers big upside potential… but it also comes with a number of risks and red flags. As always, when dealing with penny stocks, we advise caution before entering into such high-risk ventures. Remember to think before you trade… understand the risks… and if you decide to trade, stick to your stop-losses!

Happy Trading!

Trades of the Day Research Team

READ BEFORE TRADING PENNY STOCKS: The allure of penny stocks lies in their potential to deliver massive gains in a short period of time. However, in exchange for that opportunity, most penny stocks carry tremendous risk. They can be extremely volatile and are susceptible to “pump and dump” schemes and fraud.

Unlike regular stocks, the financial condition of most penny stock companies can be extremely difficult to analyze, as the majority of such stocks are traded on over-the-counter (OTC) exchanges, which are typically less transparent and less regulated than the major exchanges. In fact, in the penny stock space, it’s often easier to spot warning signs and red flags than it is to identify a sound investment. Nevertheless, we do our best to identify short-term trade opportunities in this exciting space because we know some of our readers are looking for high-risk, high-reward ideas. We just urge you to make sure you fully understand the risks before making any of these trades.